Larimar Therapeutics shareholders elect Class I directors, approve all proposals at 2024 annual meeting

Larimar Therapeutics, Inc.

Jonathan Leff and Jeffrey Sherman re-elected as Class I directors with ~40.7M and ~51.1M votes for, respectively.
Advisory vote on executive compensation approved with ~48.8M for, ~2.4M against.
Ratification of PricewaterhouseCoopers LLP as auditor for FY2024 approved with ~59.6M for.
Amendment to certificate of incorporation regarding officer exculpation approved with ~50.9M for.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.